Sign in
Taking people in United StatesNo phase

AMEND TS Early Feasibility Study

Key facts

Who runs it
Valcare Medical Ltd.
Where
Atlanta, Houston, Indianapolis, La Jolla, Murray, Nashville, New York, Phoenix, Portland, San Antonio, and The Bronx, United StatesSee the 11 sites
Trial code
Status
Recruiting
People taking part
15 people, planned
Started
11 Sept 2025
Expected to end
Apr 2027
Type of study
Interventional
Treatments tested
  • This study will evaluate the safety and functionality of the AMEND™ Trans-Septal System for annuloplasty as a therapy for mitral regurgitation.
Record updated
7 January 2026

Who can take part

Age
21 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 40 criteriaShow less

Who can take part

  • Patient age >21
  • The patient will benefit from isolated mitral valve annuloplasty for mitral regurgitation without the need for concomitant cardiovascular surgical procedures such as coronary artery bypass or another valve reconstruction or replacement
  • Symptomatic functional MR≥3+
  • NYHA functional capacity ≥2
  • LV Ejection Fraction > 30%, LVEDD < 68 mm
  • The subject meets the anatomical eligibility criteria for available implant size(s)
  • The subject is at high risk for mitral valve surgery as assessed by the center's heart team for mitral procedures
  • The subject has been stable and on a stable pharmacological regimen for heart failure for at least 1 month prior to inclusion
  • Femoral vein access and transseptal device access is determined to be feasible by the implanting investigator
  • The patient is willing to comply with study procedures and is available to return to the implant center for follow-up visits
  • Informed consent documentation signed and dated confirming that the patient has been adequately informed of all aspects related to his/her participation in the clinical study and is willing to participate

Who cannot take part

  • Previous or active endocarditis
  • A previously implanted prosthetic aortic valve or mitral intervention
  • Cardiovascular intervention within 30 days prior to study procedure
  • The patient has had an ischemic coronary event within 30 days prior to study procedure
  • Drug or alcohol abuse
  • Participation in concomitant research studies of investigational products
  • Implant or revision of any rhythm management device (cardiac resynchronization therapy (CRT) or cardiac resynchronization therapy device (CRT-D)) or implantable cardioverter defibrillator within the prior month
  • Status 1 heart transplantation or prior orthotopic heart transplantation
  • Cardiac or non-cardiac major or progressive disease, which in the investigator's discretion produces an unacceptable increased risk to the patient
  • Active infection
  • The patient has clinically significant coronary artery disease requiring re- vascularization
  • A known allergy to nickel
  • Severe allergy to contrast media
  • Pulmonary systolic hypertension (estimated SPAP > 70 mmHg at rest), determined by echocardiography
  • Any planned cardiac surgery or interventions within the next 7 months
  • GFR <30 ml/min
  • The subject is unable to take anti-platelet or anti-coagulant medications
  • Pregnant (for women in the reproductive age, blood HCG test result positive) or lactating patient
  • The patient has mitral incompetence where an annuloplasty ring will not contribute to its repair
  • Life expectancy of less than 12 months
  • The subject is non-operable and is not eligible for TEER, to allow bailout
  • Heavily calcified mitral annulus or leaflets
  • The subject is contraindicated to general anesthesia
  • Significant right ventricle dysfunction
  • Left atrial thrombus
  • A cerebral vascular event (CVA or TIA) within the past 12 months
  • A mitral valve anatomy which may preclude proper AMEND™ treatment
  • Hypotension (systolic pressure <90 mm Hg) or requirement for inotropic support or mechanical hemodynamic support
  • Subjects in whom transesophageal echocardiography is contraindicated or high risk

Where in United States

  • Piedmont HealthcareAtlanta, United StatesContact: Caryn BernsteinNot yet recruiting
  • University of Texas Health Science Center (UTH)Houston, United StatesContact: Anna MeneresTaking people
  • Ascension St. VincentIndianapolis, United StatesContact: Jena StanleyTaking people
  • Scripps HealthLa Jolla, United StatesContact: Crystal SerneoNot yet recruiting
  • Intermountain HealthMurray, United StatesContact: Erika HummelNot yet recruiting
  • Saint Thomas Research InstituteNashville, United StatesContact: Emily NormandinNot yet recruiting
  • Columbia University Medical Center - CUMCNew York, United StatesContact: Krystal GarciaTaking people
  • Banner-University Medical Center PhoenixPhoenix, United StatesContact: Karen MoylenTaking people
  • Oregon Health & Science University (OHSU)Portland, United StatesContact: Ashtyn ChamberlandTaking people
  • Methodist Hospital HCASan Antonio, United StatesContact: Jaymee LopezTaking people
  • Montefiore Medical CenterThe Bronx, United StatesContact: Tammy Rodriguez GuzmanNot yet recruiting

About the trial

What the trial wants to find out

Valcare Medical AMEND Trans-Septal System is a mitral valve repair annuloplasty ring implanted in a trans-catheter method intended for correction of mitral regurgitation. It is designed to be used as standalone therapy or in combination with other repair treatments.

The group in the trial

  • prospective, single arm, open trial to evaluate the safety, functionality of the AMEND TS SystemTreatment being tested

    The AMEND TS EFS is a prospective, single arm, open clinical trial designed to evaluate the safety and functionality of the AMENDTM Trans-Septal System for MR reduction in patients suffering from functional mitral regurgitation. This study will evaluate the safety and functionality of the AMEND™ Trans-Septal System for annuloplasty as a therapy for mitral regurgitation.

    Treatment: This study will evaluate the safety and functionality of the AMEND™ Trans-Septal System for annuloplasty as a therapy for mitral regurgitation.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The AMEND TS Early Feasibility Study is a Prospective, Single-arm, Multi-center Study to Evaluate the Safety and Function of the AMEND(TM) Trans-Septal System for MR Reduction; Up to 15 Subjects Will be Enrolled in up to 7 Investigational Centers in the U.S. and Canada With a 30d Safety Endpoint
Record updated
7 January 2026